BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 3127078)

  • 41. Interaction of mutants of tissue-type plasminogen activator with liver cells: effect of domain deletions.
    Kuiper J; Van't Hof A; Otter M; Biessen EA; Rijken DC; van Berkel TJ
    Biochem J; 1996 Feb; 313 ( Pt 3)(Pt 3):775-80. PubMed ID: 8611154
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Different receptors mediate the hepatic catabolism of tissue-type plasminogen activator and urokinase.
    Krause J; Seydel W; Heinzel G; Tanswell P
    Biochem J; 1990 May; 267(3):647-52. PubMed ID: 2160232
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibition of one-chain and two-chain forms of human tissue-type plasminogen activator by the fast-acting inhibitor of plasminogen activator in vitro and in vivo.
    Colucci M; Paramo JA; Collen D
    J Lab Clin Med; 1986 Jul; 108(1):53-9. PubMed ID: 3086473
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neoglycoproteins as tools in glycohistochemistry.
    Gabius HJ; Bardosi A
    Prog Histochem Cytochem; 1991; 22(3):1-16. PubMed ID: 2047523
    [No Abstract]   [Full Text] [Related]  

  • 45. Pharmacokinetics in chimpanzees of recombinant human tissue-type plasminogen activator produced in mouse C127 and Chinese hamster ovary cells.
    Tanigawara Y; Hori R; Okumura K; Tsuji J; Shimizu N; Noma S; Suzuki J; Livingston DJ; Richards SM; Keyes LD
    Chem Pharm Bull (Tokyo); 1990 Feb; 38(2):517-22. PubMed ID: 2110870
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tissue plasminogen activator is endocytosed by mannose and galactose receptors of rat liver cells.
    Smedsrød B; Einarsson M; Pertoft H
    Thromb Haemost; 1988 Jun; 59(3):480-4. PubMed ID: 2847350
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pregnancy zone protein-tissue-type plasminogen activator complexes bind to low-density lipoprotein receptor-related protein (LRP).
    Sánchez MC; Chiabrando GA; Vides MA
    Arch Biochem Biophys; 2001 May; 389(2):218-22. PubMed ID: 11339811
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of heparin, aspirin and a synthetic platelet glycoprotein IIb-IIIa receptor antagonist (Ro 43-5054) on coronary artery reperfusion and reocclusion after thrombolysis with tissue-type plasminogen activator in the dog.
    Roux SP; Tschopp TB; Kuhn H; Steiner B; Hadváry P
    J Pharmacol Exp Ther; 1993 Jan; 264(1):501-8. PubMed ID: 8423548
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Imaging of thrombi with tissue-type plasminogen activator rendered enzymatically inactive and conjugated to a residualizing label.
    Ord JM; Hasapes J; Daugherty A; Thorpe SR; Bergmann SR; Sobel BE
    Circulation; 1992 Jan; 85(1):288-97. PubMed ID: 1728459
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A slow clearing, fibrin-specific, PAI-1 resistant variant of t-PA (T103N, KHRR 296-299 AAAA).
    Paoni NF; Keyt BA; Refino CJ; Chow AM; Nguyen HV; Berleau LT; Badillo J; Peña LC; Brady K; Wurm FM
    Thromb Haemost; 1993 Aug; 70(2):307-12. PubMed ID: 8236140
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Analysis of site-specific N-glycosylation of recombinant Desmodus rotundus salivary plasminogen activator rDSPA alpha 1 expressed in Chinese hamster ovary cells.
    Gohlke M; Nuck R; Kannicht C; Grunow D; Baude G; Donner P; Reutter W
    Glycobiology; 1997 Feb; 7(1):67-77. PubMed ID: 9061366
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications.
    Lucore CL; Sobel BE
    Circulation; 1988 Mar; 77(3):660-9. PubMed ID: 2449299
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
    Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
    J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of liver blood flow on the pharmacokinetics of tissue-type plasminogen activator (alteplase) during thrombolysis in patients with acute myocardial infarction.
    van Griensven JM; Koster RW; Burggraaf J; Huisman LG; Kluft C; Kroon R; Schoemaker RC; Cohen AF
    Clin Pharmacol Ther; 1998 Jan; 63(1):39-47. PubMed ID: 9465840
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Influence of the fast-acting inhibitor of plasminogen activator on in vivo thrombolysis induced by tissue-type plasminogen activator in rabbits. Interference of tissue-derived components.
    Colucci M; Paramo JA; Stassen JM; Collen D
    J Clin Invest; 1986 Jul; 78(1):138-44. PubMed ID: 3088040
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Primary structure of N-linked carbohydrate chains of a human chimeric plasminogen activator K2tu-PA expressed in Chinese hamster ovary cells.
    Bergwerff AA; van Oostrum J; Asselbergs FA; Bürgi R; Hokke CH; Kamerling JP; Vliegenthart JF
    Eur J Biochem; 1993 Mar; 212(3):639-56. PubMed ID: 8462541
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An experimental multiple-organ model for the study of regional net release/uptake rates of tissue-type plasminogen activator in the intact pig.
    Jern C; Seeman-Lodding H; Biber B; Winsö O; Jern S
    Thromb Haemost; 1997 Sep; 78(3):1150-6. PubMed ID: 9308769
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characterization of the hepatic disposition of lanoteplase, a rationally designed variant of tissue plasminogen activator in rodents.
    Komoriya K; Kato Y; Hayashi Y; Ohsuye K; Nishigaki R; Sugiyama Y
    Drug Metab Dispos; 2007 Mar; 35(3):469-75. PubMed ID: 17178768
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
    Collen D; Stassen JM; Yasuda T; Refino C; Paoni N; Keyt B; Roskams T; Guerrero JL; Lijnen HR; Gold HK
    Thromb Haemost; 1994 Jul; 72(1):98-104. PubMed ID: 7974384
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cellular degradation of free and inhibitor-bound tissue-type plasminogen activator--requirement for a co-receptor?
    Camani C; Gavin O; Kruithof EK
    Thromb Haemost; 2000 Feb; 83(2):290-6. PubMed ID: 10739388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.